Stefan Paepke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stefan Paepke has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
M. Kiechle
Frauenklinik des Klinikums rechts der Isar der Technischen Universität München, München
2 shared publications- Matthias Warm
Breast center, Department of Gynecology, University Hospital Cologne, Cologne, Germany
2 shared publications - Peter Andreas Fasching
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
2 shared publications R. Ohlinger
Ernst-Moritz-Arndt-Universität Greifswald, Klinik u. Poliklinik für Frauenheilkunde u. Geburtshilfe, Greifswald
2 shared publications- Sherko Kümmel
Breast center, Essen Mitte Clinics, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany
2 shared publications A. Rezai
Fachbereich Medizin, Ludwig-Maximilians-Universität
1 shared publication
Latest Publications
- 19 February 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (5) , 1437-1442
The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?
Estimating distant recurrence risk in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer is still challenging. EndoPredict® is a gene expression-based test predicting the likelihood of recurrent disease. We analyzed the difference in oncological decision making with and without the knowledge of gene expression tests.
- 19 February 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 299 (5) , 1437-1442
The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?
Estimating distant recurrence risk in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer is still challenging. EndoPredict® is a gene expression-based test predicting the likelihood of recurrent disease. We analyzed the difference in oncological decision making with and without the knowledge of gene expression tests.
- Open Access
- 22 May 2018
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 15 (02) , 115-119
Prepectoral implant placement in plastic-reconstructive breast surgery – a contribution to the discussion
Implant-based breast reconstruction has gained a high and increasing level of importance both nationally and internationally in recent years and covers a wide spectrum of reconstruction techniques. The standard procedure in nipple-sparing subcutaneous mastectomies is currently performed by placing the implant into a subpectoral pocket beneath the pectoralis muscle. The use of implant-based reconstructive techniques with the need for internal support to reconstruct the inframammary fold, to cover the implant at the lower pole and to provide a stable but flexible implant position has become relevant and led to the introduction of heterologous materials such as acellular dermal matrices and synthetic meshes. Although the safety and aesthetics of this approach have produced good results, prepectoral techniques add a whole new dimension with the development of the next generation of acellular dermal matrices and, especially, titanised implant pockets created specifically for prepectoral implant placement [1] have brought about a renaissance in muscle-sparing reconstructive techniques. These preserve the natural anatomy, thereby avoiding the adverse effects associated with submuscular reconstruction, including preservation of full shoulder function, minimising postoperative pain and the risk of bleeding and haematoma, and animation deformities such as “jumping breast phenomenon”. A new method of implant-based breast reconstruction is therefore available and must be analysed regarding indications and benefits.
- 22 May 2018
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 15 (02) , 115-119
Open AccessPrepectoral implant placement in plastic-reconstructive breast surgery – a contribution to the discussion
Implant-based breast reconstruction has gained a high and increasing level of importance both nationally and internationally in recent years and covers a wide spectrum of reconstruction techniques. The standard procedure in nipple-sparing subcutaneous mastectomies is currently performed by placing the implant into a subpectoral pocket beneath the pectoralis muscle. The use of implant-based reconstructive techniques with the need for internal support to reconstruct the inframammary fold, to cover the implant at the lower pole and to provide a stable but flexible implant position has become relevant and led to the introduction of heterologous materials such as acellular dermal matrices and synthetic meshes. Although the safety and aesthetics of this approach have produced good results, prepectoral techniques add a whole new dimension with the development of the next generation of acellular dermal matrices and, especially, titanised implant pockets created specifically for prepectoral implant placement [1] have brought about a renaissance in muscle-sparing reconstructive techniques. These preserve the natural anatomy, thereby avoiding the adverse effects associated with submuscular reconstruction, including preservation of full shoulder function, minimising postoperative pain and the risk of bleeding and haematoma, and animation deformities such as “jumping breast phenomenon”. A new method of implant-based breast reconstruction is therefore available and must be analysed regarding indications and benefits.
- 24 March 2014
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 11 (01) , 21-25
Komplikationen in der Mammachirurgie – Serome
Mit einer Inzidenz von bis zu 81 % stehen Serome an der Spitze postoperativer Nebenwirkungen. Jedoch werden nur ca. 15 % durch Folgekomplikationen wie Infektionen und sekundäre Wundheilungsstörungen zum klinisch relevanten Problem. Die Entstehung von Seromen ist multifaktoriell, basiert auf der Reaktion auf mechanische und thermische Gewebezerstörung, verstärkt durch exsudativ-(pro)inflammatorische Prozesse, und ist eng mit dem entstandenen „Totraum“ im Wundgebiet verknüpft. Der Umfang des operativen Eingriffs im Bereich der Brust und Axilla ist nur bedingt für die Serombildung verantwortlich. Die Untersuchungen einer Vielzahl von hypothetischen Risikofaktoren zeigten keine konklusiven Resultate. Eine Vielzahl von Serom-minimierenden Verfahren wurde untersucht. Fibrin-basierte Gewebeklebstoffe führten nicht zu relevanten Verbesserungen. Die Art und Weise der Gewebedissektion wurde in einigen Untersuchungen als beeinflussender Faktor identifiziert. Einzig die Verminderung des Totraums der Wundhöhle durch innere Nähte führt bisher zu signifikanter Seromminderung mit den Nachteilen der Operationszeitverlängerung und der Ausbildung innerer Narben. Die Drainierung von Wunden ist Behandlungsstandard, der jedoch nicht unumstritten ist. Erste positive Erfahrungen wurden mit einem Urethan-basierten Gewebeklebstoff gemacht, der zur chemisch-mechanischen Verkleinerung des Wundtotraums mit oder ohne Verwendung von Drainagen führt. Prospektive Studien, die zur Identifizierung der effektivsten Strategie führen sollen, sind in der Planung. With an incidence of up to 81 % seroma remains one of the most common sequelae following breast surgery, with about 15 % of these leading to secondary complications such as infection and wound healing disorders. The formation of seroma is multifactorial, based initially on the response of the tissue to mechanical and possibly thermal injury. It is reinforced by exudative (pro)inflammatory processes and “shear forces” and is closely linked to the “dead space” created in the wound area through tissue undermining. The extent of surgery in the chest and axilla is however only partially responsible for seroma formation. Investigations into additional hypothetical risk factors have shown no conclusive results. A range of approaches to avoiding or minimizing seroma formation and related complications in breast surgery was examined. The type of dissection used has been suggested as a factor in some studies, e.g with preliminary efforts by ultrasonic dissectors but no convincing evidence that alternatives to standard electrocautery for dissection are associated with reduced seroma rates. Closure of dead space is widely viewed as important in reducing or avoiding seroma related complications. Use of fibrin-based tissue sealants has not led to relevant improvements. Reports on mechanical closure of the dead space with suturing techniques have demonstrated the efficacy of this approach, but with the drawback of significantly longer operating times and inner scar formation. Use of suction drains to eliminate dead space and avoid or reduce seroma formation has been considered as a “standard of care” by many even though clear evidence supporting the efficacy of drains in this regard is lacking. More recently also preliminary positive results have been obtained with a urethane-based tissue adhesive used for chemical/mechanical closure of the dead space both with and without drain placement. Prospective studies should be performed to identify the most effective strategy.
- 24 March 2014
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 11 (01) , 21-25
Komplikationen in der Mammachirurgie – Serome
Mit einer Inzidenz von bis zu 81 % stehen Serome an der Spitze postoperativer Nebenwirkungen. Jedoch werden nur ca. 15 % durch Folgekomplikationen wie Infektionen und sekundäre Wundheilungsstörungen zum klinisch relevanten Problem. Die Entstehung von Seromen ist multifaktoriell, basiert auf der Reaktion auf mechanische und thermische Gewebezerstörung, verstärkt durch exsudativ-(pro)inflammatorische Prozesse, und ist eng mit dem entstandenen „Totraum“ im Wundgebiet verknüpft. Der Umfang des operativen Eingriffs im Bereich der Brust und Axilla ist nur bedingt für die Serombildung verantwortlich. Die Untersuchungen einer Vielzahl von hypothetischen Risikofaktoren zeigten keine konklusiven Resultate. Eine Vielzahl von Serom-minimierenden Verfahren wurde untersucht. Fibrin-basierte Gewebeklebstoffe führten nicht zu relevanten Verbesserungen. Die Art und Weise der Gewebedissektion wurde in einigen Untersuchungen als beeinflussender Faktor identifiziert. Einzig die Verminderung des Totraums der Wundhöhle durch innere Nähte führt bisher zu signifikanter Seromminderung mit den Nachteilen der Operationszeitverlängerung und der Ausbildung innerer Narben. Die Drainierung von Wunden ist Behandlungsstandard, der jedoch nicht unumstritten ist. Erste positive Erfahrungen wurden mit einem Urethan-basierten Gewebeklebstoff gemacht, der zur chemisch-mechanischen Verkleinerung des Wundtotraums mit oder ohne Verwendung von Drainagen führt. Prospektive Studien, die zur Identifizierung der effektivsten Strategie führen sollen, sind in der Planung. With an incidence of up to 81 % seroma remains one of the most common sequelae following breast surgery, with about 15 % of these leading to secondary complications such as infection and wound healing disorders. The formation of seroma is multifactorial, based initially on the response of the tissue to mechanical and possibly thermal injury. It is reinforced by exudative (pro)inflammatory processes and “shear forces” and is closely linked to the “dead space” created in the wound area through tissue undermining. The extent of surgery in the chest and axilla is however only partially responsible for seroma formation. Investigations into additional hypothetical risk factors have shown no conclusive results. A range of approaches to avoiding or minimizing seroma formation and related complications in breast surgery was examined. The type of dissection used has been suggested as a factor in some studies, e.g with preliminary efforts by ultrasonic dissectors but no convincing evidence that alternatives to standard electrocautery for dissection are associated with reduced seroma rates. Closure of dead space is widely viewed as important in reducing or avoiding seroma related complications. Use of fibrin-based tissue sealants has not led to relevant improvements. Reports on mechanical closure of the dead space with suturing techniques have demonstrated the efficacy of this approach, but with the drawback of significantly longer operating times and inner scar formation. Use of suction drains to eliminate dead space and avoid or reduce seroma formation has been considered as a “standard of care” by many even though clear evidence supporting the efficacy of drains in this regard is lacking. More recently also preliminary positive results have been obtained with a urethane-based tissue adhesive used for chemical/mechanical closure of the dead space both with and without drain placement. Prospective studies should be performed to identify the most effective strategy.
- Open Access
- 5 February 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 66
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data. Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm. No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.
- 5 February 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 66
Open AccessFemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL). Patients were randomly assigned to receive either LET 2.5 mg/day (n = 79) or the combination of LET 2.5 mg/day and a total of seven infusions of ZOL 4 mg every 4 weeks (n = 89) for 6 months. Primary endpoint was clinical response rate as assessed by mammogram readings. The study was terminated prematurely due to insufficient recruitment. We report here on an exploratory analysis of this data. Central assessment of tumor sizes during the treatment period was available for 131 patients (66 LET, 65 LET + ZOL). Clinical responses (complete or partial) were seen in 54.5% (95% CI: 41.8-66.9) of the patients in the LET arm and 69.2% (95% CI: 56.6-80.1) of those in the LET + ZOL arm (P = 0.106). A multivariate model showed an OR of 1.72 (95% CI: 0.83-3.59) for the experimental arm. No increase in the clinical response rate was observed with the addition of ZOL to a neoadjuvant treatment regimen with LET. However a trend towards a better reponse in the LET + ZOL arm could be observed. This trend is consistent with previous studies that have investigated the addition of ZOL to chemotherapy, and it may support the evidence for a direct antitumor action of zoledronic acid.
- 17 December 2012
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 9 (04) , 217-222
Einsatz des teilresorbierbaren Zweikomponenten-Polypropylen-Vicryl-Meshs (SERAGYN®BR) als Gewebeinterponat in der plastisch-rekonstruktiven Mammachirurgie – erste Erfahrungen
Einleitung: Der Einsatz von azellulärer Dermis und Netzinterponaten in der plastisch-rekonstruktiven Mammachirurgie wird bei bisher exzellenten Erfahrungen durch die Leitlinien der Arbeitsgemeinschaft Gynäkologische Onkologie gleichrangig zu Rekonstruktionen mit körpereigenem Gewebe empfohlen. Seit 8/2010 steht ein teilresorbierbares Zweikomponentennetz zur Verfügung, dessen Grundfaden als Trägergerüst aus resorbierbarem Polyglykolsäure-Caprolacton (PGA-CL) besteht und nach Resorption Polypropyleneinzelfilamente als Dauerimplantat zurücklässt. Die Materialeigenschaften des Netzes sprechen für einen Einsatz in der plastisch-rekonstruktiven Mammachirurgie bei Implantateinlage. Material und Methoden: Von 3/11 – 6/12 führten wir bei 28 Patientinnen (Alter im Median: 47 Jahre) subkutane Mastektomien mit Einlage des teilresorbierbaren Zweikomponentennetzes (n = 34) als sofortrekonstruktive Methode durch. Ergebnisse: Die Brustdrüsenabladate wiesen ein Durchschnittsgewicht von 329 g (120 – 580 g) auf, die Implantate ein Durchschnittsvolumen von 335 cm³ (125 – 515 cm³). Die Implantateinlage erfolgte vornehmlich als subpectorale Implantateinlage; in 7 Fällen wurde das Implantat ausschließlich netzbedeckt. Wir verzeichneten keine Netzarosion, 4 Wundinfektionen, von denen 2 operativ korrigiert werden mussten und weitere 3 ungeplante Folgeoperationen mit zweimaliger Entfernung der gesamten Rekonstruktion. Als Hauptrisikofaktoren für Frühkomplikationen wurden Voroperationen, Bestrahlung und ein periareolärer operativer Zugang identifiziert. Die mittlere Drainagedauer betrug 8 Tage. Diskussion: Der Einsatz großporiger, teilresorbierbarer Implantate führt durch die Materialkombination und -konstruktion, die Reduktion des Fremdkörperanteils und die gesteigerten Weichheit nach Resorption zu Formstabilität und Geschmeidigkeit der Rekonstruktion. Die bisher geringe Fallzahl und die kurze Nachbeobachtungszeit limitieren die Gültigkeit der Aussagen. Initiiert wurde eine prospektive multizentrische Untersuchung, die Erfahrungen anhand von 100 Patientinnen zusammenführen soll. Darauf aufbauend wird ein Vergleich der zur Verfügung stehenden Gewebeinterponate geführt werden. Introduction: Based on excellent experiences, using Acellular Dermis and mesh implants in plastic-reconstructive breast surgery is recommended by the German Society of Gynecologic Oncology (AGO) equally ranking to reconstructions with body’s own tissue. Since August 2010a partially absorbable two-component mesh is available, whose basic filaments consist of absorbable polyglycolic acid-caprolactone (PGA‑CL) leaving single polypropylene filaments as long term implants after resorption. The material properties of the mesh argue for its use in plastic-reconstructive breast surgery. Material and Methods: Between March 2011 and June 2012, 28 subcutaneous mastectomies were performed using partially absorbable two-component meshes (n = 34) as an instant-reconstructive method. Median age of patients was 47 years. Results: Mastectomy weights ranged between 120 and 580 g (average 329 g), implant volumes ranged between 125 and 515 cm3 (average 335 cm3). Implants were mainly done subpectorally; in 7 cases the implant was covered solely by the mesh. Mesh arrosions could not be detected, 4 wound infections (2 had to be surgically revised), and 3 unscheduled secondary operations making a removal of the whole construction necessary in two cases. Main risk factors for early complications were previous surgeries, radiation, and a periareolar surgical access. The mean duration of drainage lasted for 8 days. Discussion: The use of large-porous, partially absorbable implants leads to a more stable and flexible form of the reconstruction. The hitherto number of cases and the short follow-up time limit the validity of our conclusions. Eventually, a prospective multicenter study has been initiated combining the experiences with 100 patients. Based on that data, a comparison the available tissue implants will be possible.
- 17 December 2012
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 9 (04) , 217-222
Einsatz des teilresorbierbaren Zweikomponenten-Polypropylen-Vicryl-Meshs (SERAGYN®BR) als Gewebeinterponat in der plastisch-rekonstruktiven Mammachirurgie – erste Erfahrungen
Einleitung: Der Einsatz von azellulärer Dermis und Netzinterponaten in der plastisch-rekonstruktiven Mammachirurgie wird bei bisher exzellenten Erfahrungen durch die Leitlinien der Arbeitsgemeinschaft Gynäkologische Onkologie gleichrangig zu Rekonstruktionen mit körpereigenem Gewebe empfohlen. Seit 8/2010 steht ein teilresorbierbares Zweikomponentennetz zur Verfügung, dessen Grundfaden als Trägergerüst aus resorbierbarem Polyglykolsäure-Caprolacton (PGA-CL) besteht und nach Resorption Polypropyleneinzelfilamente als Dauerimplantat zurücklässt. Die Materialeigenschaften des Netzes sprechen für einen Einsatz in der plastisch-rekonstruktiven Mammachirurgie bei Implantateinlage. Material und Methoden: Von 3/11 – 6/12 führten wir bei 28 Patientinnen (Alter im Median: 47 Jahre) subkutane Mastektomien mit Einlage des teilresorbierbaren Zweikomponentennetzes (n = 34) als sofortrekonstruktive Methode durch. Ergebnisse: Die Brustdrüsenabladate wiesen ein Durchschnittsgewicht von 329 g (120 – 580 g) auf, die Implantate ein Durchschnittsvolumen von 335 cm³ (125 – 515 cm³). Die Implantateinlage erfolgte vornehmlich als subpectorale Implantateinlage; in 7 Fällen wurde das Implantat ausschließlich netzbedeckt. Wir verzeichneten keine Netzarosion, 4 Wundinfektionen, von denen 2 operativ korrigiert werden mussten und weitere 3 ungeplante Folgeoperationen mit zweimaliger Entfernung der gesamten Rekonstruktion. Als Hauptrisikofaktoren für Frühkomplikationen wurden Voroperationen, Bestrahlung und ein periareolärer operativer Zugang identifiziert. Die mittlere Drainagedauer betrug 8 Tage. Diskussion: Der Einsatz großporiger, teilresorbierbarer Implantate führt durch die Materialkombination und -konstruktion, die Reduktion des Fremdkörperanteils und die gesteigerten Weichheit nach Resorption zu Formstabilität und Geschmeidigkeit der Rekonstruktion. Die bisher geringe Fallzahl und die kurze Nachbeobachtungszeit limitieren die Gültigkeit der Aussagen. Initiiert wurde eine prospektive multizentrische Untersuchung, die Erfahrungen anhand von 100 Patientinnen zusammenführen soll. Darauf aufbauend wird ein Vergleich der zur Verfügung stehenden Gewebeinterponate geführt werden. Introduction: Based on excellent experiences, using Acellular Dermis and mesh implants in plastic-reconstructive breast surgery is recommended by the German Society of Gynecologic Oncology (AGO) equally ranking to reconstructions with body’s own tissue. Since August 2010a partially absorbable two-component mesh is available, whose basic filaments consist of absorbable polyglycolic acid-caprolactone (PGA‑CL) leaving single polypropylene filaments as long term implants after resorption. The material properties of the mesh argue for its use in plastic-reconstructive breast surgery. Material and Methods: Between March 2011 and June 2012, 28 subcutaneous mastectomies were performed using partially absorbable two-component meshes (n = 34) as an instant-reconstructive method. Median age of patients was 47 years. Results: Mastectomy weights ranged between 120 and 580 g (average 329 g), implant volumes ranged between 125 and 515 cm3 (average 335 cm3). Implants were mainly done subpectorally; in 7 cases the implant was covered solely by the mesh. Mesh arrosions could not be detected, 4 wound infections (2 had to be surgically revised), and 3 unscheduled secondary operations making a removal of the whole construction necessary in two cases. Main risk factors for early complications were previous surgeries, radiation, and a periareolar surgical access. The mean duration of drainage lasted for 8 days. Discussion: The use of large-porous, partially absorbable implants leads to a more stable and flexible form of the reconstruction. The hitherto number of cases and the short follow-up time limit the validity of our conclusions. Eventually, a prospective multicenter study has been initiated combining the experiences with 100 patients. Based on that data, a comparison the available tissue implants will be possible.